ZA200705540B - Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation - Google Patents

Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation

Info

Publication number
ZA200705540B
ZA200705540B ZA200705540A ZA200705540A ZA200705540B ZA 200705540 B ZA200705540 B ZA 200705540B ZA 200705540 A ZA200705540 A ZA 200705540A ZA 200705540 A ZA200705540 A ZA 200705540A ZA 200705540 B ZA200705540 B ZA 200705540B
Authority
ZA
South Africa
Prior art keywords
prevention
compositions
treatment
airway inflammation
pde4 modulators
Prior art date
Application number
ZA200705540A
Other languages
English (en)
Inventor
Jerome B Zeldis
Patricia E W Rohane
Peter H Schafer
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ZA200705540B publication Critical patent/ZA200705540B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
ZA200705540A 2004-12-13 2005-12-12 Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation ZA200705540B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63498204P 2004-12-13 2004-12-13

Publications (1)

Publication Number Publication Date
ZA200705540B true ZA200705540B (en) 2009-01-28

Family

ID=36121316

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705540A ZA200705540B (en) 2004-12-13 2005-12-12 Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation

Country Status (13)

Country Link
US (1) US20060148882A1 (enExample)
EP (1) EP1838294A1 (enExample)
JP (1) JP2008523102A (enExample)
KR (1) KR20070092276A (enExample)
CN (1) CN101111235A (enExample)
AR (1) AR052047A1 (enExample)
AU (1) AU2005316593A1 (enExample)
BR (1) BRPI0519030A2 (enExample)
CA (1) CA2590903A1 (enExample)
IL (1) IL183858A0 (enExample)
MX (1) MX2007006992A (enExample)
WO (1) WO2006065814A1 (enExample)
ZA (1) ZA200705540B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20070007945A (ko) * 2004-04-23 2007-01-16 셀진 코포레이션 폐 고혈압증의 치료 및 관리를 위한 ｐｄｅ4 조절인자의사용 방법 및 그를 포함하는 조성물
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
KR20110116049A (ko) * 2009-02-10 2011-10-24 셀진 코포레이션 결핵의 치료, 예방 및 관리를 위한 ｐｄｅ4 조절제를 포함하는 조성물 및 사용 방법
MX2011012122A (es) 2009-05-14 2012-02-28 Tianjin Hemay Bio Tech Co Ltd Derivados de tiofeno.
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
US20140018404A1 (en) 2010-12-16 2014-01-16 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
CN103402980B (zh) * 2011-01-10 2016-06-29 细胞基因公司 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
WO2012096859A2 (en) * 2011-01-10 2012-07-19 Celgene Corporation Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
EP2683376B1 (en) 2011-03-07 2018-11-28 Celgene Corporation Methods for treating diseases using isoindoline compounds
KR101889757B1 (ko) 2011-04-28 2018-08-20 셀진 코포레이션 자가 면역 및 염증 질환의 치료 및 관리를 위한 ｐｄｅ4 저해제를 이용한 방법 및 조성물
WO2014151180A1 (en) 2013-03-14 2014-09-25 Celgene Corporation Treatment of psoriatic arthritis using apremilast
EP3096749B1 (en) * 2014-01-24 2019-05-15 Celgene Corporation Methods for the treatment of obesity using apremilast
EP3188745A1 (en) 2014-08-15 2017-07-12 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
US10011611B2 (en) 2015-08-14 2018-07-03 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
CA3034785C (en) * 2016-08-22 2022-11-15 Shijiazhuang Sagacity New Drug Development Co., Ltd. Pde4 inhibitor
DK3590924T3 (da) * 2017-02-28 2022-01-03 Kangpu Biopharmaceuticals Inc Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf
WO2018167142A1 (en) * 2017-03-16 2018-09-20 Takeda Gmbh Treatment of idiopathic pulmonary fibrosis
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7354948B2 (en) * 2002-11-06 2008-04-08 Celgene Corporation Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
AU2003294311B8 (en) * 2002-11-18 2008-06-05 Celgene Corporation Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CA2511843C (en) * 2002-12-30 2012-04-24 Celgene Corporation Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
KR20070007945A (ko) * 2004-04-23 2007-01-16 셀진 코포레이션 폐 고혈압증의 치료 및 관리를 위한 ｐｄｅ4 조절인자의사용 방법 및 그를 포함하는 조성물
US20080267905A1 (en) * 2004-05-05 2008-10-30 Celgene Corporation Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same

Also Published As

Publication number Publication date
IL183858A0 (en) 2007-10-31
AR052047A1 (es) 2007-02-28
CN101111235A (zh) 2008-01-23
AU2005316593A1 (en) 2006-06-22
US20060148882A1 (en) 2006-07-06
CA2590903A1 (en) 2006-06-22
JP2008523102A (ja) 2008-07-03
BRPI0519030A2 (pt) 2008-12-23
WO2006065814A1 (en) 2006-06-22
MX2007006992A (es) 2007-08-03
EP1838294A1 (en) 2007-10-03
KR20070092276A (ko) 2007-09-12

Similar Documents

Publication Publication Date Title
IL183858A0 (en) Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
ZA200704677B (en) Compositions and methods for the treatment of autism
EP2318033B8 (en) Compositions for the treatment of pain and/or inflammation
SI1594867T1 (sl) Fenilacetamidi in njihova uporaba kot glukokinazni modulatorji
IL182574A0 (en) Gpr41 and modulators thereof for the treatment of insulin-related disorders
IL178860A (en) Certain chemical entities, preparations and processes
ZA200702007B (en) Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
AU2003291480A8 (en) Composition for the prevention and treatment of inflammation of the ear
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
EP1755589A4 (en) METHOD OF USING PDE4 MODULATORS AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1814567A4 (en) USE OF MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING AND PREVENTING INFECTIONS
IL198721A0 (en) Acat inhibitors and their use in the prevention or treatment of fibrosis
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
IL181777A0 (en) Gpr43 and modulators thereof for the treatment of metabolic-related disorders
EP1885351A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN
EP1812797A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HYPERPROLIFERATIVE DISEASES
EP1776956A4 (en) PREVENTIVE AND / OR THERAPEUTIC AGENT FOR CALCIPENIA
GB0425633D0 (en) Topical formulations for use in the treatment or prevention of dermatological conditions
EP1819724A4 (en) BETA 2-GLYCOPROTEIN I COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
IL180526A0 (en) Composition for the prevention and treatment of allergic inflammatory disease